Efficacy and Safety of Emodepside in Adolescents and Adults Infected With Hookworm

Exclusion Criteria

• •Pregnant or lactating and/or planning to become pregnant within three months after drug treatment;
• •Type 1 and/or 2 diabetes;
• •Psychiatric disorders;
• •History of ophthalmological conditions;
• •Presence or history of major systemic or chronic illnesses, as assessed by a medical doctor, during initial clinical assessment;
• •Suffers from severe anaemia (Hb \< 80 g/l);
• •Received anthelminthic treatment within past four weeks;
• •Attending other clinical trials during the study;
• •Received strong CYP3A4 inducers or inhibitors as well as concomitant treatments that are relevant substrate for CYP3A4 such as clarithromycin, erythromycin and rifampicin;
• •Received strong P-gp inhibitors as well as concomitant treatments that are relevant substrates for P-gp such as clotrimazole and ritonavir.
• •Participated in stage I trials of this protocol